NEUTRAL / EVENT-HEAVY Friday's broad rebound and VIX retreat repaired one session, not the week. Sticky core CPI, a near-5% 10-year yield, oil above $100 and Wednesday's FOMC keep risk asymmetric.
Generated 08:32:42 CEST (Europe/Rome); data cutoff 08:32 CEST. Saturday mode: U.S., European and Asian figures are Friday Sep. 11 closes; Treasury par yields are the latest official Sep. 10 observations. Cash markets are closed and Friday futures settlements are not weekend indications. All times are CEST unless stated.
Prices: Yahoo chart API, cross-checked with Yahoo's Friday wrap and CNN Markets. Rates: FRED 2Y and FRED 10Y. Week return compares Sep. 11 with Sep. 4 close; VIX direction is interpreted inversely for risk.
August headline CPI was +0.4% m/m and +3.4% y/y, both as expected; core was +0.3% m/m versus +0.2% expected and +2.4% y/y. Energy rose 2.1% m/m and 16.3% y/y. Friday reporting put Sep. 16 hike odds around 82%–87%, up sharply from Thursday. BLS · Reuters
All 11 S&P sectors were positive Friday and VIX fell to 15.84, yet all four major U.S. indices finished the week lower; Russell underperformed at −2.41%. Asia fell Friday while Europe rebounded. Yahoo
WTI/Brent eased to $100.05/$104.61 after Thursday's surge, but the reported closure of Saudi Arabia's East-West pipeline after attacks preserved supply risk. A verified reopening/de-escalation would be bullish duration; further disruption is the largest inflation tail risk. Yahoo live coverage
| Prior call | Friday evidence | Audit verdict |
|---|---|---|
| ORCL conditional long Hold >$159.25 then reclaim $161.63; invalidation close <$152.94. | Opened $164.43, high $166.00, low $149.84, close $150.28. | Failed / invalidated Threshold traded, but “hold” cannot be proven from daily bars; therefore no assumed fill. Any triggered interpretation was invalidated by the close. Threshold-to-close was −7.02%. |
| VRT avoid/bearish Failed $255 reclaim then break <$248; cancel on close >$263. | Low $251.84; close $257.06 (+3.60%). | No trigger Price never broke $248; cancellation level also not reached. Avoid stance preserved capital versus chasing a short. |
| IONQ avoid/bearish Trigger only on close <$36.78; weakens >$38.14. | Close $36.75, three cents below trigger. | Triggered at close No performance can be measured until the next tradable session. Extreme squeeze/gap risk. |
| AMD avoid Long only close >$521.10; bearish only <$500 after failed reclaim. | High $521.06; close $516.13. | No trigger Neither condition occurred. The near-touch is not a breakout. |
| QCOM watch Close >$180.40; stronger >$183.49. | High $185.46; close $181.97. | First confirmation Closed above $180.40 but not $183.49. No fill had been specified; upgrade to conditional bullish, not a recorded gain. |
| RGTI / VKTX / NVO watches | RGTI $15.27; VKTX $31.98; NVO $43.07. | No trigger Required closes >$15.81, data plus >$33.68, and >$44.56 respectively did not occur. |
Audit source: Friday OHLC from Yahoo chart API. Daily bars do not reveal exact intraday sequencing; ambiguous fills are deliberately not invented.
Exchange/risk: NYSE; large-cap, high-beta AI networking. Classification: relative-strength breakout watch. Applicable horizon: day and 1–4 weeks; 3–12+ months only after fresh fundamental/valuation work. Direction: uncertain through FOMC.
Thesis/catalyst/evidence: Friday +5.61% to $199.59 on 4.64M shares versus Thursday 2.81M; it outperformed a +0.96% Nasdaq and reclaimed the prior week's area. Counterargument: one relief day after a down week is insufficient and no new company release was verified.
Entry/confirmation: close above Friday high $200.25 with positive semiconductor/networking breadth; avoid a gap chase. Invalidation/downside: close below $192.10, then $188.99 is risk. Key risks: hyperscaler concentration, AI capex, competition, supply, valuation, rates and export controls. price
Exchange/risk: Nasdaq; large-cap semiconductor/customer-catalyst risk. Classification: prior watch upgraded after first confirmation. Applicable horizon: day/1–4 weeks; longer term only after contract economics. Direction: uncertain.
Thesis/catalyst/evidence: close $181.97 (+2.88%) met the prior >$180.40 condition and traded to $185.46. AWS collaboration supports an AI infrastructure narrative. Counterargument: it closed below the stronger $183.49 checkpoint and below Friday's high. Qualcomm release
Entry/confirmation: close >$185.46, preferably after FOMC. Invalidation/downside: close <$175.74; $172 is next risk area. Risks: customer concentration, warrants/dilution, competition, margins, export controls, rates.
Exchange/risk: NYSE; mega-cap cloud with high capex/debt/event risk. Classification: avoid; bearish only on confirmation. Applicable horizon: day/1–4 weeks; not a structural long-term short. Direction: uncertain; short loss unlimited.
Evidence: gap-up open $164.43 failed violently; close $150.28 below Thursday's $152.94 invalidation on 79.5M shares. Counterargument: OCI growth and $664B RPO support demand, and oversold rebound risk is high.
Entry/confirmation: avoid longs until close >$159.24; bearish only after failed $152.94 reclaim and break <$149.84. Invalidation/downside: bearish case weakens >$159.24; below $149.84 downside is undefined. Risks: squeeze, debt/credit, customer concentration, RPO conversion, construction/power, margins, FOMC. Borrow terms unknown. 10-Q
Exchange/risk: NYSE ADR; large-cap pharma, FX/pricing/clinical risk. Classification: persistent relative weakness. Applicable horizon: 1–4 weeks; no automatic 3–12+ month short. Direction: uncertain.
Evidence: $43.07 (−2.14%) versus S&P +0.86%, below every close this week. Counterargument: established semaglutide franchise and Sep. 29 EASD evidence flow can reverse sentiment; price is not clinical evidence.
Entry/confirmation: avoid; bearish only on close <$42.72. Invalidation/downside: regain $44.56; stronger above $46.60. Risks: clinical surprise, pricing/access, supply, patents, FX, competition and squeeze. Borrow terms unknown. Novo/EASD
Exchange/risk: NYSE; high-volatility quantum/acquisition/dilution. Classification: prior bearish close trigger; confirmation required. Applicable horizon: day/1–4 weeks only. Direction: uncertain; short loss unlimited.
Evidence: $36.75 close triggered the prior <$36.78 condition but by only $0.03; 2026 outlook includes SkyWater. Counterargument: integration, government programs and roadmap milestones can create abrupt squeezes.
Entry/confirmation: bearish only on break <$36.33 after a failed reclaim of $36.78. Invalidation/downside: close >$38.14; below $36.33 downside undefined. Risks: acquisition integration, technical success, awards, burn, dilution, gaps and liquidity. Borrow terms unknown. IonQ
Class/horizon/direction: high-beta mega-cap; 1–4 week breakout watch; uncertain. Thesis: +2.49% and weekly outperformance. Counter: Friday high $521.06 stopped four cents below prior $521.10 condition. Confirmation: close >$521.10, stronger >$525. Invalidation/downside: <$501.35; then $500. Risks: valuation, competition, HBM/supply, concentration, exports, FOMC. price
Class/horizon/direction: high-beta large-cap; reversal watch, day/1–4 weeks; uncertain. Thesis: +3.60% rebound after a two-day plunge. Counter: still below $262.89/$263 and down 8.37% from Sep. 4. Confirmation: close >$258.78, stronger >$263. Invalidation/downside: <$251.84, then $248.13. Risks: squeeze/whipsaw, valuation, orders, execution, input/energy costs, rates. price
Class/horizon/direction: small-cap clinical biotech; 1–4 weeks around Q3 data, 3–12+ months only after full analysis; uncertain. Study: Phase 1 maintenance, ~180 randomized participants; safety/tolerability/PK objectives, weight change exploratory. Evidence: Q3 issuer guidance; $502M cash at Jun. 30. Counter: no date, Q2 loss $128M, limited study size and oral tolerability history. Confirmation: acceptable safety and maintained weight plus close >$33.05/$33.68. Invalidation/downside: poor durability/safety, delay, or close <$31.70. Risks: binary efficacy/safety, FDA path, competition, manufacturing, burn/dilution. primary release
Class/horizon/direction: small-cap, dilution/technical risk; day/1–4 weeks only; uncertain. Thesis: $100M definitive U.S. agreement targets concrete bottlenecks. Counter: government receives minority equity; milestones, funding and roadmap execution condition value. Confirmation: close >$15.81, stronger >$16.40. Invalidation/downside: <$15.08 then $14.84. Risks: dilution, cash burn, appropriations, fidelity/roadmap, liquidity and gaps. Rigetti
Scores are 0–100. Higher Risk means riskier. Thesis Confidence measures evidence quality—not probability of profit. All entries are conditional; no fill is assumed.
Bias: Monday confirmation only; reduce exposure into Wednesday FOMC. ANET >$200.25 and QCOM >$185.46 are conditional longs; ORCL <$149.84 and IONQ <$36.33 are only confirmation levels, not predictions.
Biggest risk: weekend oil/geopolitical gap and FOMC whipsaw. Regime invalidation: broad S&P break above 7,677 with falling yields/oil upgrades risk; close below 7,592 with VIX >17.84 restores risk-off.
Bias: selective and smaller through FOMC; favor confirmed networking/semiconductor relative strength over cloud-financing stress and pre-profit quantum.
Biggest risk: oil-driven inflation plus a hike/hawkish projections. Invalidation: 10Y sustainably below 4.80% and broad indices above Sep. 4 closes would improve duration setups; renewed 10Y >5% weakens them.
Bias: AI demand remains credible, but insist on revenue conversion, margins, FCF and balance-sheet capacity. Quantum requires independently validated utility/unit economics; peptide biotech requires full datasets, regulatory clarity and runway.
Biggest risk: capital-cost shock, concentration, dilution or technical/clinical failure. Thesis invalidation: sustained deterioration in orders, margins, cash generation, roadmap evidence or clinical benefit—not a single volatile session.